Clinical Trials on Haemophilia A

Total 4979 results

BioMarin Pharmaceutical

Enrolling by invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) (GENEr8-LTE)

Hemophilia A

United Kingdom, United States
BioMarin Pharmaceutical

Completed

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg (GENEr8-2)

Hemophilia A

United States
Hospices Civils de Lyon

Completed

Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease (M-HEMORRH'AGE)

Hemophilia

France
Beijing Children's Hospital

Unknown

Pharmacokinetic (PK)Research on Chinese Children of Hemophilia (PK)

Pharmacokinetics

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Epidemiology and Immunology of Hemophilia A Inhibitors

Hemophilia A | Blood Disease
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of FVIII Gene Therapy for Hemophilia A

Hemophilia A

China
University of Texas Southwestern Medical Center

Recruiting

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Hemophilia A | Factor VIII

United States
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
BioMarin Pharmaceutical

Completed

A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A (SAAVY)

Hemophilia A

United States
BioMarin Pharmaceutical

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3)

Hemophilia A

United States, Australia, Taiwan, Brazil
Hospital Universitario La Fe

Unknown

Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients

Hemophilia A | Factor VIII

Spain
Beijing Children's Hospital

Unknown

Individualized Prophylaxis for Severe Hemophilia A Children

Hemophilia
PTC Therapeutics
Genzyme, a Sanofi Company

Terminated

Study of Ataluren (PTC124) in Hemophilia A and B

Hemophilia A | Hemophilia B

United States, Canada, France, Italy
Sheba Medical Center

Unknown

Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders

Severe Hemophilia

Israel
New York Presbyterian Hospital

Completed

The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs

Hemophilia A | Hemophilia B

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

Hemophilia B | Allergic Reactions

France, Italy, United States, Austria, Belgium, Spain, United Kingdom, Canada, Germany
BioMarin Pharmaceutical

Recruiting

A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)

Hemophilia A

Argentina
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

Hemophilia A

China
BioMarin Pharmaceutical

Active, not recruiting

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A (GENEr8-JPN)

Hemophilia A

Japan
Spark Therapeutics

Completed

A Gene Transfer Study for Hemophilia A

Hemophilia A

United States, Australia, Canada, Israel, Thailand
BioMarin Pharmaceutical

Active, not recruiting

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (BMN 270-301)

Hemophilia A

United States, Taiwan, United Kingdom, Australia, Israel, Belgium, Brazil, France, Germany, Italy, Korea, Republic of, South Africa, Spain
Baxalta now part of Shire
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Active, not recruiting

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Hemophilia A

United States, Spain, Hungary, Italy, Germany, Austria, France
Hoffmann-La Roche

Completed

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Hemophilia A | Healthy Volunteers

China
Chulalongkorn University

Completed

Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A

Hemophilia A | Prophylaxis

Thailand
Centers for Disease Control and Prevention

Completed

Joint Outcome Study

Hemophilia A
Universidad del Azuay

Completed

Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador (VWD)

Hemophilia A | Hemophilia B | Von Willebrand Disease

Ecuador
Great Ormond Street Hospital for Children NHS Foundation...

Completed

Prevalence of Autistic Spectrum Disorder (ASD) in Children With Haemophilia

Autism Spectrum Disorder | Attention Deficit Hyperactivity Disorder | Social Communication Disorder | Haemophilia
Baxalta now part of Shire

Terminated

Osteoporosis and MRI Study in Hemophilia

Hemophilia A | Hemophilia B | Bone Mineral Density

United States
Laboratoire français de Fractionnement et de Biotechnologies

Recruiting

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM (SCOPE HIM)

Hemophilia

United States, Thailand, Mexico, Turkey, South Africa, Malaysia
Sanofi

Recruiting

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (ATLAS-NEO)

Hemophilia

Greece, Korea, Republic of, France, Taiwan, Italy, Spain, United States, Canada, China, Germany, India, Japan, Mexico, South Africa, Turkey, Poland, Saudi Arabia
Bayer

Active, not recruiting

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding (HA-SAFE)

Hemophilia A

Spain, Germany, Austria, Greece, Italy, Slovenia
Takeda

Active, not recruiting

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Hemophilia A

China
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 Continuation

Hemophilia A

United States, Spain, Netherlands, Australia, Czechia, Korea, Republic of, Taiwan, Poland, Bulgaria, United Kingdom, Germany, Turkey, Israel, Malaysia, Ukraine, Russian Federation, Austria, Switzerland, Japan, Hong Kong, Lithuania, Roman... and more
Pfizer

Completed

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients

Hemophilia A

India
Bayer

Completed

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Hemophilia A

Bulgaria
Pfizer

Withdrawn

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

Hemophilia A
Taipei Medical University Hospital
Sanofi

Enrolling by invitation

Observational Study of Long-Term Joint Health Outcome in Hemophilia Patient

Hemophilia | Arthropathy

Taiwan
Craig Seaman

Terminated

Weight-based Dosing in Hemophilia A

Hemophilia

United States
Bayer

Completed

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Hemophilia A

Belgium, New Zealand, Netherlands, Greece, United Kingdom, Austria, United States, Italy, Romania, Bulgaria, Canada, Israel, Poland, Lithuania, Norway, Argentina, Spain
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B (DYNAMO)

Hemophilia

Netherlands, Austria, Australia, Belgium, Canada, Finland, Germany, Italy, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Genetic Susceptibility to Factor VIII Inhibitors

Hemophilia

Sweden
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

Hemophilia A

China
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...
Sintesi Research Srl

Unknown

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients (ITI)

Hemophilia A

India, Egypt
Sheba Medical Center

Terminated

The Influence of "Karate" on Bleeding in Hemophilic Patients.

Hemophilia A
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Hemophilia A

United States, New Zealand, Australia, Hungary, Sweden, Austria, Poland, Romania
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
Wayne State University
Genentech, Inc.

Recruiting

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis (STEP)

Hemophilia A

United States
Prof. Dr. Dr. Thomas Hilberg
Takeda; University of Bonn

Recruiting

Association Between Individual Clotting Factor Level Monitoring and the Risk of Bleeding Whilst Physical Active Conditions (AIM-Active)

Hemophilia A

Germany
Institute of Hematology & Blood Diseases Hospital

Recruiting

Gene Therapy for Chinese Hemophilia A (HA)

Hemophilia A | Gene Therapy

China

Clinical Trials on Haemophilia A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations